ACADIA Pharmaceuticals (NASDAQ:ACAD) has tumbled 5.53% during the past week, however, the bigger picture is still very bullish; the stocks have advanced and posted positive gains of 9.9% in the last four weeks. The stocks have underperformed the S&P 500 by 4.4% during the past week but ACADIA Pharmaceuticals (NASDAQ:ACAD) it has outperformed the index in 4 weeks by 8.9%.
ACADIA Pharmaceuticals (NASDAQ:ACAD): The stock opened at $38.53 on Friday but the bulls could not build on the opening and the stock topped out at $38.69 for the day. The stock traded down to $37.34 during the day, due to lack of any buying support eventually closed down at $37.41 with a loss of -2.45% for the day. The stock had closed at $38.35 on the previous day. The total traded volume was 2,931,313 shares.
The company shares have dropped -12.14% from its 1 Year high price. On Jul 15, 2015, the shares registered one year high at $51.99 and the one year low was seen on Feb 9, 2016. The 50-Day Moving Average price is $34.14 and the 200 Day Moving Average price is recorded at $28.60.
On the companys insider trading activities, The Securities and Exchange Commission has divulged that Baity Glenn, (EVP AND GC) of Acadia Pharmaceuticals Inc, had unloaded 7,000 shares at an average price of $20.8 in a transaction dated on March 2, 2016. The total value of the transaction was worth $145,600.
Many analysts have stated their opinion on the company shares. Equity Analysts at the Brokerage Firm, Leerink Swann, downgrades their rating on the shares of ACADIA Pharmaceuticals (NASDAQ:ACAD). Leerink Swann has a Market Perform rating on the shares. Previously, the analysts had a Outperform rating on the shares. The rating by the firm was issued on May 3, 2016. Currently the company Insiders own 22.42% of ACADIA Pharmaceuticals shares according to the proxy statements. Institutional Investors own 97.28% of ACADIA Pharmaceuticals shares.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for the treatment of neurological and related central nervous system disorders. The Companys drug candidate NUPLAZID (pimavanserin) is under development for the treatment of Parkinsons disease psychosis, Alzheimers disease psychosis, Schizophrenia and Sleep disturbances. The Company is also conducting preclinical programs for alpha adrenergic agonists indicated for the treatment of chronic pain and muscarinic drugs for the treatment of glaucoma. NUPLAZID has an active ingredient pimavanserin, is a selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT2A receptors that was discovered by the Company. The Company in collaboration with Allergan, has discovered and engaged in the development of small-molecule product candidates, such as alpha adrenergic agonists and muscarinic receptors.